Unlocking the Potential of Genetic Medicines

David Kirn, Co-Founder and CEO of 4DMT, sits down with Neil to discuss the limits of existing AAV vectors and how his company is using its Therapeutic Vector Evolution platform to invent customized vectors that allows it to take a disease specific approach to unlock the potential of genetic medicines.

Om Podcasten

Join Neil Littman on The Bioverge Podcast as he explores the intersection of bio x tech and features the entrepreneurs, investors, and industry leaders who are revolutionizing healthcare and bringing science fiction to life.